Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6621 · 1 trial · 1 indication
• Number of participants with AEs, AESIs, SAEs, including AEs leading to discontinuation of study intervention and clinically significant alterations from baseline in laboratory parameters, vital signs, ECGs and physical examination results
• A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.
• Number of participants with a PSA response rate
| Arm | Type | Description |
|---|---|---|
| Module 1 - Part A (Dose Escalation) | EXPERIMENTAL | AZD6621 Monotherapy - Administration route 1 |
| Module 2 - Part A (Dose Escalation) | EXPERIMENTAL | AZD6621 Monotherapy - Administration route 2 |
| Module 1/2 - Part B1 (Dose Expansion) | EXPERIMENTAL | AZD6621 Monotherapy - Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 1 (RDE1) |
| Module 1/2 - Part B2 (Dose Expansion) | EXPERIMENTAL | AZD6621 Monotherapy - Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 2 (RDE2) |
| Name | Type | Description |
|---|---|---|
| AZD6621 | DRUG | A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8 |
Inclusion Criteria 1. Capable of giving signed informed consent and complying to the study protocol. 2. Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form. 3. ≥ 18 years of age at the time of signing the informed consent form. 4. Participants wi...
Top 20 of 53 competitors
AZD6621 is an investigational small molecule being studied for the treatment of metastatic prostate cancer in adult male patients. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
The molecular target of AZD6621 has not been disclosed in available information. It is a small molecule modality being investigated for its safety, efficacy, and pharmacokinetics in patients with metastatic prostate cancer.
AZD6621 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's potential in prostate cancer.
AZD6621 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied for safety and effectiveness in patients.
AZD6621 is being evaluated in a Phase 1 clinical trial registered as NCT07192614. This study is recruiting adult male participants with metastatic prostate cancer across multiple countries, including the United States, Belgium, Canada, China, Japan, Netherlands, South Korea, Spain, and the United Kingdom.
No alternative names for AZD6621 have been reported. It is identified solely by its developmental code name AZD6621 in clinical trial registries and scientific literature.